在 2 型糖尿病患者中，阿洛酮糖摄入对葡萄糖稳态、代谢参数、肠降血糖素水平和炎症标志物的短期影响：一项双盲、随机、对照交叉临床试验。

Short-term effects of allulose consumption on glucose homeostasis, metabolic parameters, incretin levels, and inflammatory markers in patients with type 2 diabetes: a double-blind, randomized, controlled crossover clinical trial.

机构信息

Siriraj Diabetes Center of Excellence, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Siriraj Center of Research Excellence for Diabetes, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

出版信息

Eur J Nutr. 2023 Oct;62(7):2939-2948. doi: 10.1007/s00394-023-03205-w. Epub 2023 Jul 11.

DOI:10.1007/s00394-023-03205-w

PMID:37432472

Abstract

PURPOSE

Allulose is a rare monosaccharide with almost zero calories. There is no study of short-term allulose consumption in patients with type 2 diabetes (T2D). Thus, we aimed to study the effect of allulose consumption for 12 weeks on glucose homeostasis, lipid profile, body composition, incretin levels, and inflammatory markers in patients with T2D.

METHODS

A double-blind, randomized, controlled crossover study was conducted on sixteen patients with T2D. Patients were randomly assigned to allulose 7 g twice daily or aspartame 0.03 g twice daily for 12 weeks. After a 2-week washout, patients were crossed over to the other sweetener for an additional 12 weeks. Oral glucose tolerance tests, laboratory measurements, and dual-energy X-ray absorptiometry were conducted before and after each phase.

RESULTS

This study revealed that short-term allulose consumption exerted no significant effect on glucose homeostasis, incretin levels, or body composition but significantly increased MCP-1 levels (259 ± 101 pg/ml at baseline vs. 297 ± 108 pg/mL after 12 weeks of allulose, p = 0.002). High-density lipoprotein cholesterol (HDL-C) significantly decreased from 51 ± 13 mg/dl at baseline to 41 ± 12 mg/dL after 12 weeks of allulose, p < 0.001.

CONCLUSION

Twelve weeks of allulose consumption had a neutral effect on glucose homeostasis, body composition, and incretin levels. Additionally, it decreased HDL-C levels and increased MCP-1 levels.

TRIAL REGISTRATION

This trial was retrospectively registered on the Thai Clinical Trials Registry (TCTR20220516006) on December 5, 2022.

摘要

目的

阿洛酮糖是一种罕见的单糖，几乎不含热量。目前尚无关于 2 型糖尿病（T2D）患者短期摄入阿洛酮糖的研究。因此，我们旨在研究 12 周内摄入阿洛酮糖对 T2D 患者血糖稳态、血脂谱、身体成分、肠降血糖素水平和炎症标志物的影响。

方法

对 16 名 T2D 患者进行了一项双盲、随机、对照交叉研究。患者被随机分配到每天两次服用 7 克阿洛酮糖或每天两次服用 0.03 克阿斯巴甜，持续 12 周。在 2 周洗脱期后，患者交叉服用另一种甜味剂，再持续 12 周。在每个阶段前后进行口服葡萄糖耐量试验、实验室测量和双能 X 射线吸收法检查。

结果

本研究表明，短期阿洛酮糖摄入对血糖稳态、肠降血糖素水平或身体成分没有显著影响，但显著增加了单核细胞趋化蛋白 1（MCP-1）水平（基线时为 259±101 pg/ml，12 周后为 297±108 pg/ml，p=0.002）。高密度脂蛋白胆固醇（HDL-C）从基线时的 51±13 mg/dl 显著下降至 12 周后阿洛酮糖时的 41±12 mg/dL，p<0.001。